21 unknown. 21 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Unknown 21 |
| Phase 2 | 2 | Unknown 2 |
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells - Diffuse Large B Cell Lymphoma, Burkitt Lymphoma | Phase 3 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2021-09-14 | 2023-07-25 |
| Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation Zebutinib&BR or Zebutinib&FCR - Chronic Lymphocytic Leukemia | Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 45 | 2021-09-01 | 2021-07-28 |
| ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL ICP-022, Chlorambucil, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Unknown | Beijing InnoCare Pharma Tech Co., Ltd. | 218 | 2021-01-08 | 2023-06-05 |
| Combination of Ibrutinib and As2O3 in the Treatment of CLL Ibrutinib combined with As2O3, ibrutinib - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | Unknown | Peking University People's Hospital | 70 | 2016-12-01 | 2016-04-29 |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Ibrutinib - Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas | Phase 3 | Unknown | The University of Hong Kong | 62 | 2016-11-01 | 2018-04-12 |
| Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL Chidamide, Dasatinib - Leukemia, Leukemia, Acute | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 120 | 2016-02-14 | 2022-07-01 |
| Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia FFP+HDMP+Rituximab - Chronic Lymphocytic Leukemia | Phase 3 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 100 | 2012-01-01 | 2012-08-22 |
| A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment Ofatumumab, Chlorambucil, Bendamustine - Chronic Lymphocytic Leukaemia | Phase 3 | Unknown | University of Liverpool | 670 | 2011-12-01 | 2012-10-15 |
| Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia Bendamustine Hydrochloride Injection, Chlorambucil - Chronic Lymphocytic Leukemia, Leukemia | Phase 3 | Unknown | Shandong Lanjin Pharmaceuticals Co.,Ltd | 96 | 2011-01-01 | 2012-08-06 |
| Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Anti-Thymocyte Globulin (Rabbit), Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin) - Hematologic Malignancies | Phase 3 | Unknown | McMaster University | 198 | 2010-04-01 | 2010-10-08 |
| Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas Rituximab, Rituximab / observation - Follicular Lymphomas, Immunocytomas | Phase 3 | Unknown | Jurgen Barth | 1272 | 2009-04-01 | 2024-08-22 |
| Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain ketamine hydrochloride, pharmacogenomic studies, questionnaire administration - Cancer | Phase 3 | Unknown | University of Glasgow | 214 | 2009-04-01 | 2011-05-13 |
| Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia amoxicillin-clavulanate potassium, ciprofloxacin, psychosocial assessment and care - Brain and Central Nervous System Tumors, Lymphoma | Phase 3 | Unknown | Clatterbridge Centre for Oncology | 400 | 2007-07-01 | 2013-08-12 |
| Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer epoetin alfa, epoetin beta, iron dextran complex - Anemia, Leukemia | Phase 3 | Unknown | St. Bartholomew's Hospital | 80 | 2007-01-01 | 2014-01-10 |
| Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia cefepime hydrochloride, levofloxacin - Fever, Sweats, and Hot Flashes, Infection | Phase 3 | Unknown | Jonsson Comprehensive Cancer Center | 2001-09-01 | 2013-12-19 | |
| Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia chlorambucil, cyclophosphamide, fludarabine phosphate - Leukemia | Phase 3 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 2001-03-01 | 2008-07-24 | |
| Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma immunoscintigraphy, technetium Tc 99m epratuzumab - Lymphoma | Phase 2 / Phase 3 | Unknown | Gilead Sciences | 60 | 1997-03-01 | 2021-08-16 |
| Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma immunoscintigraphy, technetium Tc 99m epratuzumab - Lymphoma | Phase 3 | Unknown | Gilead Sciences | 100 | 1997-03-01 | 2021-08-16 |
| Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome busulfan, cyclophosphamide, idarubicin - Leukemia, Lymphoma | Phase 3 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 207 | 1997-03-01 | 2009-02-09 |
| Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma recombinant interferon alfa - Lymphoma | Phase 3 | Unknown | Lymphoma Study Association | 360 | 1995-10-01 | 2013-08-07 |
Showing 20 of 21. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (19) · Lymphoma, Follicular (12) · Lymphoma, Mantle-Cell (10) · Lymphoma (9) · Lymphoma, B-Cell, Marginal Zone (9) · Lymphoma, Non-Hodgkin (9) · Burkitt Lymphoma (8) · Lymphoma, Large B-Cell, Diffuse (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Lymphoma, Large-Cell, Immunoblastic (7) · Leukemia (6) · Hodgkin Disease (4) · Waldenstrom Macroglobulinemia (4) · Immunoblastic Lymphadenopathy (3) · Intraocular Lymphoma (3)
Hematologic Diseases (21) · Hemic and Lymphatic Diseases (21) · Immune System Diseases (21) · Immunoproliferative Disorders (21) · Leukemia, Lymphoid (21) · Lymphatic Diseases (21) · Lymphoproliferative Disorders (21) · Neoplasms by Histologic Type (21) · Chronic Disease (19) · Disease Attributes (19) · Neoplasms (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Leukemia (15)
Chlorambucil (5) · Rituximab (3) · Bendamustine Hydrochloride (2) · Cyclophosphamide (2) · Idarubicin (2) · Interferon-alpha (2) · Radioimmunodetection (2) · epratuzumab (2) · ibrutinib (2) · Amoxicillin-Potassium Clavulanate Combination (1) · Antilymphocyte Serum (1) · Arsenic Trioxide (1) · Busulfan (1) · Cefepime (1) · Ciprofloxacin (1)
European Organisation for Research and Treatment of Cancer - EORTC (2) · Gilead Sciences (2) · Nanfang Hospital, Southern Medical University (2) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Clatterbridge Centre for Oncology (1) · Jonsson Comprehensive Cancer Center (1) · Jurgen Barth (1) · Lymphoma Study Association (1) · McMaster University (1) · Peking University People's Hospital (1) · Scotland and Newcastle Lymphoma Group (1) · Shandong Lanjin Pharmaceuticals Co.,Ltd (1) · St. Bartholomew's Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1) · The University of Hong Kong (1)
United Kingdom (6) · China (5) · Italy (4) · United States (3) · Austria (2) · Belgium (2) · France (2) · Germany (2) · Netherlands (2) · Sweden (2) · Switzerland (2) · Canada (1) · Czechia (1) · Hong Kong (1) · Hungary (1)
William A. Wegener, MD, PhD (2) · Barry J.A. Laird, MD (1) · Bertrand Coiffier, MD (1) · Branimir Jaksic, MD, PhD (1) · Ernest Marshall, MD (1) · Irwin Walker, MD (1) · Lu G Qiu, M.D. (1) · Marie T. Fallon (1) · Mary C. Territo, MD (1) · Mathias Rummel, Dr (1) · Samir G Agrawal, MD, PhD (1) · Stephen J. Proctor, MD, FRCP, FRCPath (1) · Theo De Witte, MD, PhD (1) · Wei Xu, M.D., Ph.D. (1) · Xiao-Jun Huang, Doctor (1)
PMID 31756535, PMID 31958417, PMID 37341189, PMID 40313965, PMID 41123227, PMID 42402625